Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases

• US 9,409,983 B2
• Filed: 07/23/2010
• Issued: 08/09/2016
• Est. Priority Date: 07/23/2009
• Status: Active Grant

• Current Assignee: Board of Trustees of The University of Illinois, University of Chicago, University of Illinois at Chicago (University of Illinois)
• Original Assignee: Board of Trustees of The University of Illinois
• Inventors: Garcia, Joe G. N.
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US12/842,773
• Publication Number:
  US 20110020364A1
• Time in Patent Office: 2,209 Days
• Field of Search: 424/158.1, 514/1.1
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C07K 16/243 Colony Stimulating Factors
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2310/14 interfering N.A.

Abstract

The present invention concerns methods and compositions involving inhibitors of Pre-B Cell Colony Enhancing Factor (PBEF) for inflammatory conditions and diseases, including acute lung injury (ALI), ventilator-induced lung injury (VILI), and acute respiratory distress syndrome (ARDS). The present invention also concerns biomarkers for inflammation as well as methods for screening for PBEF inhibitors.

Claims

1. A method for treatment of an inflammatory condition of the lungs or disease of the lungs in a human patient comprising administering to a human patient an effective amount of a Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor, wherein the human patient has symptoms of the inflammatory condition or disease, wherein the PBEF inhibitor is a neutralizing PBEF antibody.

2. The method of claim 1, wherein the inflammatory disease or condition of the lungs is acute lung injury (ALI), ventilator-induced lung injury (VILI), or acute respiratory distress syndrome (ARDS).

3. The method of claim 1, wherein the inhibitor is administered to the patient intravenously, intraarterially, intraperitoneally, intrapleurally, intratracheally, topically, subcutaneously, mucosally, intrapericardially, orally, or by inhalation.

4. The method of claim 1, wherein the effective amount of the Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor is administered before the human patient has been placed on a ventilator.

5. The method of claim 1, wherein the effective amount of the Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor is administered after the human patient has been placed on a ventilator.

6. A method for treating a patient with acute lung injury (ALI), ventilator-induced lung injury (VILI), or acute respiratory distress syndrome (ARDS) comprising administering to the patient an effective amount of a Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor, wherein the PBEF inhibitor is a neutralizing PBEF antibody.

7. The method of claim 6, wherein the inhibitor is administered to the patient intravenously, intraarterially, intraperitoneally, intrapleurally, intratracheally, topically, subcutaneously, mucosally, intrapericardially, orally, or by inhalation.

8. The method of claim 6, wherein the effective amount of the Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor is administered before the patient has been placed on a ventilator.

9. The method of claim 6, wherein the patient has sepsis or symptoms of sepsis.

10. The method of claim 6, wherein the effective amount of the Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor is administered after the patient has been placed on a ventilator.

11. A method for preventing ventilator-induced lung injury (VILI) in a human patient comprising administering to a human patient an effective amount of a Pre-B Cell Colony-Enhancing Factor (PBEF) inhibitor, wherein the PBEF inhibitor is a neutralizing PBEF antibody, and wherein the administration occurs before the patient is placed on a ventilator.